Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
|Articles|October 28, 2015
Valeant Responds to Drug Distribution Criticisms
Author(s)Randi Hernandez
October 28, 2015.
Advertisement
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the
BioPharm International's Randi Hernandez reports on
Advertisement
Related to this article
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
2
Where GLP-1 Development May be Headed
3
Connecting RWD to Better Understand the Patient Journey
4
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
5